Compare GE Vernova Inc (GEV) vs Lemonade Inc (LMND) Price & Performance

GE Vernova (GEV) stock trades at $1,021.20, down 4.2% over 24 hours, as it approaches its Q2 2026 earnings report on July 22. The technical picture is mixed, with a bearish overall signal but a bullish moving average crossover. Fundamentally, the company shows strong profitability with a 23.81% net margin and robust ROE of 83.23%, though valuation ratios like a P/E of 30.84 and EV/EBITDA of 109.82 appear elevated. Recent earnings have been volatile, with a significant beat in Q1 2026 but a miss in Q3 2025. Analyst sentiment remains overwhelmingly positive, with a 75% buy rating and a consensus price target of $1,260, representing over 23% upside. The company is positioned to benefit from AI-driven power demand and grid modernization, highlighted by recent news coverage and an $11 billion investment push.

The outlook for GEV is cautiously optimistic, driven by its leadership in power infrastructure and exposure to secular growth in AI and data center energy demand. Key opportunities include pricing power from scarce gas turbines, a massive global installed base, and growth in its nuclear segment with the BWRX-300 Small Modular Reactor. Primary risks include execution challenges in its Wind segment, high valuation multiples that leave little room for error, and potential volatility around earnings. The stock's recent decline may present a buying opportunity ahead of earnings for investors bullish on the long-term AI power theme.

Lemonade (LMND) trades at $64.675, down 7.79% over the past day, reflecting recent volatility. The stock shows a bullish technical signal with moving averages supporting upward momentum, while oscillators remain neutral. Fundamentally, revenue growth is robust, increasing from $257M in 2022 to $738M in 2025, but net losses persist, with a net income margin of -22.43% in 2025. Recent news highlights expansion into new states and reinsurance program improvements, driving investor interest despite profitability challenges.

The outlook for LMND is mixed; growth opportunities from AI-driven insurance expansion and state rollouts offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $69.60 price target, indicating limited near-term upside. Investors should weigh strong revenue trends against the path to profitability, with positive cash flow projected by 2026 being a key monitorable.